TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By Hutchmed (China) Limited
HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma

HUTCHMED has initiated the Phase III portion of a Phase II/III trial evaluating the combination of surufatinib, camrelizumab, nab-paclitaxel, and gemcitabine for treatment-naïve metastatic pancreatic ductal adenocarcinoma in China. Phase II results showed the combination achieved a median PFS of 7.20 months versus 5.52 months for chemotherapy alone, representing a 50.1% reduction in progression or death risk, with a favorable overall survival trend.

Insights
USBpS   neutral

Mentioned as a client of QuoteMedia with no specific performance details


HCM   positive

The company successfully advanced a promising combination therapy to Phase III based on Phase II data showing significant efficacy improvements (50.1% reduction in progression/death risk, higher ORR and DCR). The trial enrollment and positive clinical results support potential future regulatory approval and commercial opportunity in the large pancreatic cancer market.